Showing results (101-110 of 387) with videos related to
Sort By:
Pageof 39
Movement Disorders Clinical Practice|November 12, 2021
Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?Matthew J Barrett, Lana Sargent, Huma Nawaz, et al.Plos One|August 22, 2015
Effects of the Sequence of Isocaloric Meals with Different Protein Contents on Plasma Biochemical Indexes in PigsChunyan Xie, Xin Wu, Jun Li, et al.Annals of Neurology|May 13, 2026
Cognitive Impairment in Parkinson's Disease: Contributions from the Parkinson's Progression Markers InitiativeDaniel Weintraub, Roseanne D Dobkin, Michele K York, et al.Nature Reviews. Neurology|March 4, 2017
Cognitive decline in Parkinson diseaseDag Aarsland, Byron Creese, Marios Politis, et al.Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2010
Association between cognition and function in patients with Parkinson disease with and without dementiaEmily Rosenthal, Laura Brennan, Sharon Xie, et al.The Journal of Neuropsychiatry and Clinical Neurosciences|September 12, 2006
Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage studyDaniel Weintraub, Donna Taraborelli, Knashawn H Morales, et al.Nature Reviews. Neurology|January 21, 2017
The psychosis spectrum in Parkinson diseaseDominic H Ffytche, Byron Creese, Marios Politis, et al.Movement Disorders : Official Journal of the Movement Disorder Society|February 11, 2016
Research consent capacity varies with executive function and memory in Parkinson's diseaseStephen T Moelter, Daniel Weintraub, Lauren Mace, et al.Journal of Parkinson'S Disease|November 25, 2015
Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's DiseaseRagnhild E Skogseth, Kolbjorn Bronnick, Joana B Pereira, et al.European Neurology|January 30, 2009
Treatment of early Parkinson's disease. Part 1Tanya Simuni, Kelly E Lyons, Rajesh Pahwa, et al.Pageof 39